SCHEMBL1471254

SCHEMBL1471254

O=[N+]([O-])c1ccc(Oc2c(Cl)cc(S(=O)(=O)Nc3cccc(F)c3F)cc2Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
CYP2C9 P11712 1/20 0.48
THRA P10827 3/20 0.48
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
ALDH1A1 P00352 4/20 0.42
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
DDX3X O00571 1/20 0.41
PDE7A Q13946 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472433 0.90 CYP2C9 (0.49) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1472157 0.89 HPGD (0.52) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1474394 0.89 CYP2C9 (0.53) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1472276 0.88 THRA (0.52) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1471469 0.87 CYP2C9 (0.51) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1474274 0.87 CRHBP (0.52) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1471692 0.86 CRHBP (0.60) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1471432 0.85 CRHBP (0.50) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1472089 0.85 CYP2C9 (0.52) CRHBPCRHR2CYP2C9THRAHPGD
SCHEMBL1471659 0.85 THRA (0.49) CRHBPCRHR2CYP2C9THRAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A CRHBP 3873/4885CRHR2 4633/4885CYP2C9 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.